Innate and secondary humoral responses are improved by increasing the time between MVA vaccine immunizations.
Innate immunity
Vaccines
Journal
NPJ vaccines
ISSN: 2059-0105
Titre abrégé: NPJ Vaccines
Pays: England
ID NLM: 101699863
Informations de publication
Date de publication:
2020
2020
Historique:
received:
16
12
2019
accepted:
26
02
2020
entrez:
29
3
2020
pubmed:
29
3
2020
medline:
29
3
2020
Statut:
epublish
Résumé
Comprehending the mechanisms behind the impact of vaccine regimens on immunity is critical for improving vaccines. Indeed, the time-interval between immunizations may influence B and T cells, as well as innate responses. We compared two vaccine schedules using cynomolgus macaques immunized with an attenuated vaccinia virus. Two subcutaneous injections 2 weeks apart led to an impaired secondary antibody response and similar innate myeloid responses to both immunizations. In contrast, a delayed boost (2 months) improved the quality of the antibody response and involved more activated/mature innate cells, induced late after the prime and responding to the recall. The magnitude and quality of the secondary antibody response correlated with the abundance of these neutrophils, monocytes, and dendritic cells that were modified phenotypically and enriched prior to revaccination at 2 months, but not 2 weeks. These late phenotypic modifications were associated with an enhanced ex vivo cytokine production (including IL-12/23 and IL-1β) by PBMCs short after the second immunization, linking phenotype and functions. This integrated analysis reveals a deep impact of the timing between immunizations, and highlights the importance of early but also late innate responses involving phenotypical changes, in shaping humoral immunity.
Identifiants
pubmed: 32218996
doi: 10.1038/s41541-020-0175-8
pii: 175
pmc: PMC7081268
doi:
Types de publication
Journal Article
Langues
eng
Pagination
24Subventions
Organisme : Agence Nationale de la Recherche (French National Research Agency)
ID : ANR-11-INBS-0008
Organisme : Agence Nationale de la Recherche (French National Research Agency)
ID : ANR-10-EQPX-02-01
Organisme : Horizon 2020 Framework Programme (EU Framework Programme for Research and Innovation H2020)
ID : TRANSVAC GRANT N° 730964/EC
Informations de copyright
© The Author(s) 2020.
Déclaration de conflit d'intérêts
Competing interestsThe authors declare no competing interests.
Références
J Immunol. 2017 Jul 15;199(2):816-826
pubmed: 28615419
J Leukoc Biol. 1997 Jun;61(6):721-8
pubmed: 9201263
Blood. 2009 May 7;113(19):4711-9
pubmed: 19264920
Nat Med. 2005 Jul;11(7):740-7
pubmed: 15951823
Immunity. 2017 Jun 20;46(6):1073-1088.e6
pubmed: 28636956
Eur J Clin Microbiol Infect Dis. 2019 Mar;38(3):449-456
pubmed: 30719592
Cytometry A. 2016 Oct;89(10):903-913
pubmed: 27575385
J Immunol. 2016 Jun 1;196(11):4814-31
pubmed: 27183591
Eur J Pharmacol. 2015 Jul 15;759:69-83
pubmed: 25814254
Bioinformatics. 2017 Mar 1;33(5):779-781
pubmed: 27993789
Cell Rep. 2019 Aug 13;28(7):1729-1743.e5
pubmed: 31412243
Cell. 2018 Nov 29;175(6):1634-1650.e17
pubmed: 30433869
J Immunol. 2018 Oct 15;201(8):2287-2302
pubmed: 30217830
Immunity. 2019 Sep 17;51(3):573-589.e8
pubmed: 31474513
Curr Opin Biotechnol. 2004 Dec;15(6):506-12
pubmed: 15560976
J Allergy Clin Immunol. 2016 Oct;138(4):984-1010
pubmed: 27577879
Sci Transl Med. 2017 Jun 7;9(393):
pubmed: 28592561
Cytometry A. 2016 Jun;89(6):601-7
pubmed: 27061608
Discov Med. 2014 Dec;18(101):313-22
pubmed: 25549702
Nature. 2004 Mar 11;428(6979):182-5
pubmed: 15014500
PLoS Pathog. 2014 Sep 25;10(9):e1004406
pubmed: 25254512
Vaccine. 2016 Jan 20;34(4):413-423
pubmed: 26691569
Expert Rev Vaccines. 2016;15(1):91-103
pubmed: 26511884
Trends Immunol. 2013 Sep;34(9):431-9
pubmed: 23680130
J Leukoc Biol. 2019 May;105(5):1055-1073
pubmed: 30794328
Methods. 2018 Jan 1;132:66-75
pubmed: 28917725
J Innate Immun. 2014;6(2):152-8
pubmed: 24192057
Lancet Infect Dis. 2014 Dec;14(12):1196-207
pubmed: 25455987
Virchows Arch. 2001 Apr;438(4):394-7
pubmed: 11355175
Vaccine. 2017 Mar 23;35(13):1675-1682
pubmed: 28256358
PLoS Pathog. 2016 Sep 01;12(9):e1005722
pubmed: 27584152
Front Immunol. 2018 Nov 20;9:2692
pubmed: 30515169
Cytometry A. 2017 Oct;91(10):969-982
pubmed: 28444973
Sci Rep. 2018 Feb 15;8(1):3087
pubmed: 29449630
J Immunol. 2016 Aug 15;197(4):1507-16
pubmed: 27385782
Immunity. 2015 Dec 15;43(6):1186-98
pubmed: 26682988
Nat Biotechnol. 2011 Oct 02;29(10):886-91
pubmed: 21964415
J Gen Virol. 1991 May;72 ( Pt 5):1031-8
pubmed: 2033387
Immunity. 2010 Oct 29;33(4):451-63
pubmed: 21029957
Nature. 2011 Feb 24;470(7335):543-7
pubmed: 21350488
Cytometry A. 2013 May;83(5):483-94
pubmed: 23512433
Trends Immunol. 2004 Feb;25(2):98-104
pubmed: 15102369
J Allergy Clin Immunol. 1994 Dec;94(6 Pt 2):1177-83
pubmed: 7798557
J Clin Invest. 1988 Jun;81(6):1986-92
pubmed: 3133397
Cell. 2018 Jan 11;172(1-2):176-190.e19
pubmed: 29328912
J Infect Dis. 2018 Jul 13;218(4):614-623
pubmed: 29912453
J Virol. 1994 Feb;68(2):1179-85
pubmed: 8289347
Sci Rep. 2016 Dec 13;6:39097
pubmed: 27958370
Adv Virus Res. 2017;97:187-243
pubmed: 28057259
Cell. 2018 Jan 11;172(1-2):147-161.e12
pubmed: 29328910
Clin Vaccine Immunol. 2010 Jul;17(7):1055-65
pubmed: 20463105
Vaccine. 2013 Jun 24;31(29):3025-33
pubmed: 23664987
Nat Commun. 2019 Jul 4;10(1):2955
pubmed: 31273203
Proc Natl Acad Sci U S A. 2012 Oct 23;109(43):17537-42
pubmed: 22988082
Health Phys. 2015 Nov;109(5):414-26
pubmed: 26425902
Immunity. 2016 Sep 20;45(3):669-684
pubmed: 27637149
Proc Natl Acad Sci U S A. 2014 Aug 26;111(34):12288-93
pubmed: 25136130
Philos Trans R Soc Lond B Biol Sci. 2014 May 12;369(1645):20130433
pubmed: 24821919
Immunol Today. 2000 Apr;21(4):163-5
pubmed: 10740236
Cytokine Growth Factor Rev. 2002 Dec;13(6):455-81
pubmed: 12401480
Trends Cell Biol. 2009 Feb;19(2):72-80
pubmed: 19144521